Marshall Wace North America’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-3,857
Closed -$1.6M 1444
2021
Q2
$1.6M Buy
3,857
+2,335
+153% +$925K 0.01% 870
2021
Q1
$595K Sell
1,522
-663
-30% -$326K ﹤0.01% 1157
2020
Q4
$1.22M Buy
+2,185
New +$1.38M 0.01% 890
2020
Q3
Sell
-510
Closed -$404K 1218
2020
Q2
$404K Buy
+510
New +$385K ﹤0.01% 960
2020
Q1
Sell
-3,019
Closed -$3.43M 1241
2019
Q4
$3.43M Buy
3,019
+3,004
+20,027% +$3.27M 0.02% 457
2019
Q3
$17K Buy
+15
New +$22.9K ﹤0.01% 1238
2019
Q2
Sell
-36,744
Closed -$74.9M 1181
2019
Q1
$74.9M Buy
+36,744
New +$64.7M 0.53% 51
2018
Q3
Sell
-14,264
Closed -$29M 944
2018
Q2
$29M Buy
+14,264
New +$32.5M 0.16% 149
2018
Q1
Sell
-20,500
Closed -$47.3M 1434
2017
Q4
$47.3M Buy
20,500
+3,885
+23% +$7.89M 0.26% 85
2017
Q3
$29.5M Sell
16,615
-10,278
-38% -$14.4M 0.19% 147
2017
Q2
$36.6M Buy
26,893
+11,618
+76% +$14M 0.27% 88
2017
Q1
$18M Buy
+15,275
New +$15.6M 0.14% 186
2013
Q4
$267K Sell
984
-174
-15% -$48.6K 0.01% 616
2013
Q3
$404K Buy
+1,158
New +$430K 0.01% 480

Other funds holding BLUE

Marshall Wace North America's BLUE Position: Q3 2021 in Review

Marshall Wace North America sold out of bluebird bio (BLUE) in Q3 2021, closing a stake of 3,857 shares — an estimated $1.6M sold.

Marshall Wace North America first reported a position in BLUE in Q3 2013 and held it in 14 quarters. The position peaked at $74.9M in Q1 2019. 196 funds tracked by Wall St. Rank hold BLUE as of Q3 2021.

  • Marshall Wace North America reported no remaining bluebird bio position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 3,857 bluebird bio shares in Q3 2021, an estimated $1.6M.
  • Marshall Wace North America first reported a position in bluebird bio in Q3 2013 and held it in 14 quarters.
  • Marshall Wace North America's bluebird bio position peaked at $74.9M in Q1 2019.
  • 196 funds tracked by Wall St. Rank held bluebird bio as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.